Hospital Drug and Therapeutics Committees in Australia: is there a role for economic evaluation at the institutional level?
- 166 Downloads
Decisions about spending on medicines occur at different levels in the Australian health care system. This commentary describes the role of economic evaluation at the institutional (public hospital) level. In contrast to the decisions taken at the level of Federal subsidy (listing on the Pharmaceutical Benefits Scheme) formal pharmacoeonomic data analyses are usually not available, and arguably often not relevant to decision making within the public hospital setting. Future research is needed to develop and explore models of best practice and how to incorporate pharmacoeconomic evidence into local decisions.
KeywordsAustralia DTCs Economic evaluation Hospitals Pharmaceuticals
I would like to thank Professor Jo-anne Brien for her comments on an earlier version of this commentary.
Conflicts of interests
- 1.Salkeld G, Mitchell A, Hill S. Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian health policy. Sydney: Allen & Unwin; 1999. p. 115–36.Google Scholar
- 2.Australian Government Department of Health and Ageing. Review of Health Technology Assessment in Australia. Canberra 2009.Google Scholar
- 5.Holloway K, Green T. Drug and Therapeutics Committees—a practical guide (WHO/EDM/PAR/2004.1). Geneva: World Health Organization 2003.Google Scholar
- 9.Van Gool K, Gallego G, Haas M, Hall J, Viney R, RW. Incorporating economic evidence into cancer care: searching for the missing link, CHERE Working Paper 2007/3. Sydney: CHERE 2007.Google Scholar
- 10.Cancer Institute New South Wales (NSW). Review of Ambulatory/Outpatient Chemotherapy and Haematology Services in New South Wales 2005. [cited 31 May 2007]; Available from: http://www.health.nsw.gov.au/cancer_inst/profes/ambulatory_care.html.
- 11.Editorial Executive Committee. Transparency—in the eye of the beholder. Aust Prescr. 2005;28:83–4.Google Scholar
- 12.Marley J. Cost-effectiveness: the need to know. Aust Prescr. 1996;19:58–9.Google Scholar
- 13.Gallego G, Melocco T, Taylor S, Brien J. Access to high-cost drugs: decision makers’ perspectives. J Pharm Pract Res. 2005;35(1):18–20.Google Scholar